Two patents currently held, every record listed here
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2032. from the record
Of the 2 now held by other companies, 2 name Genentech Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2032
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2016 to 2036.20202024202820322036
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
1 pending application: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends May 2032 · High confidence
Also notable
Ends Nov 2033 · High confidence
Broad Spectrum Antibiotics
US 10,501,493
Granted 2019. Computed term ends 2032.
Macrocyclic Broad Spectrum Antibiotics
US 9,309,285
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2033.
Formerly held, still cited
Notable
Ends May 2035 · High confidence
The earliest of the three still in force, granted 2019 and renewed since. Its term ends first, in 2035.
now held by Genentech, Inc.
Also notable
Ends no later than Nov 2036 · Medium confidence
The newest of the three, granted 2021. It anchors the portfolio to 2036, later than anything else here. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Genentech, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 10, 2027The maintenance fee for Broad Spectrum Antibiotics (US 10,501,493) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Oct 12, 2027The maintenance fee for Macrocyclic Broad Spectrum Antibiotics (US 9,309,285) comes due Oct 12, 2027. Unpaid by Apr 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 1 largest of its 2 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Broad Spectrum Antibiotics | 1 in force | to May 2032 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,501,493 | Broad Spectrum Antibiotics In force · High confidence | In force | High confidence | |
| US 9,309,285 | Macrocyclic Broad Spectrum Antibiotics In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 2 patents in force now held by others · 2 patents ended · 1 application pending · 11 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed